In vivo cancer gene therapy by adenovirus-mediated transfer of a bifunctional yeast cytosine deaminase/uracil phosphoribosyltransferase fusion gene.
暂无分享,去创建一个
P. Leroy | P. Erbs | M. Mehtali | R. Jund | M Mehtali | R Jund | E. Régulier | P Erbs | E Regulier | J Kintz | P Leroy | Y Poitevin | F Exinger | Y. Poitevin | J. Kintz | F. Exinger | E. Régulier
[1] D. Hallahan,et al. Virally directed cytosine deaminase/5-fluorocytosine gene therapy enhances radiation response in human cancer xenografts. , 1997, Cancer research.
[2] R. Jund,et al. Genetic and Physiological Aspects of Resistance to 5-Fluoropyrimidines in Saccharomyces cerevisiae , 1970, Journal of bacteriology.
[3] D. Martin,et al. Loss of murine tumor thymidine kinase activity in vivo following 5-fluorouracil (FUra) treatment by incorporation of FUra into RNA. , 1991, Biochemical pharmacology.
[4] S. Freeman,et al. The "bystander effect": tumor regression when a fraction of the tumor mass is genetically modified. , 1993, Cancer research.
[5] P. Su,et al. Generation of 5-fluorouracil from 5-fluorocytosine by monoclonal antibody-cytosine deaminase conjugates. , 1991, Bioconjugate chemistry.
[6] P. Seth,et al. Enzyme/prodrug gene therapy approach for breast cancer using a recombinant adenovirus expressing Escherichia coli cytosine deaminase. , 1997, Cancer gene therapy.
[7] G. Tiraby,et al. Concomitant expression of E. coli cytosine deaminase and uracil phosphoribosyltransferase improves the cytotoxicity of 5-fluorocytosine. , 1998, FEMS microbiology letters.
[8] M. Lusky,et al. In Vitro and In Vivo Biology of Recombinant Adenovirus Vectors with E1, E1/E2A, or E1/E4 Deleted , 1998, Journal of Virology.
[9] J. Olsen,et al. Comparison of the effects of three different toxin genes and their levels of expression on cell growth and bystander effect in lung adenocarcinoma. , 1996, Cancer research.
[10] C. Mullen,et al. Ganciclovir chemoablation of herpes thymidine kinase suicide gene-modified tumors produces tumor necrosis and induces systemic immune responses. , 1998, Human gene therapy.
[11] A. Rehemtulla,et al. Superiority of yeast over bacterial cytosine deaminase for enzyme/prodrug gene therapy in colon cancer xenografts. , 1999, Cancer research.
[12] F. Moolten. Drug sensitivity ("suicide") genes for selective cancer chemotherapy. , 1994, Cancer gene therapy.
[13] T. A. Connors. The choice of prodrugs for gene directed enzyme prodrug therapy of cancer. , 1995, Gene therapy.
[14] R. Sikorski,et al. A system of shuttle vectors and yeast host strains designed for efficient manipulation of DNA in Saccharomyces cerevisiae. , 1989, Genetics.
[15] J. Pitts. Cancer gene therapy: A bystander effect using the gap junctional pathway , 1994, Molecular carcinogenesis.
[16] R. Duschinsky,et al. The metabolism of 5-fluorocytosine-2-14-C and of cytosine-14-C in the rat and the disposition of 5-fluorocytosine-2-14-C in man. , 1966, Biochemical pharmacology.
[17] Connors Ta. The choice of prodrugs for gene directed enzyme prodrug therapy of cancer. , 1995 .
[18] R. Warnick,et al. In vitro evidence that metabolic cooperation is responsible for the bystander effect observed with HSV tk retroviral gene therapy. , 1993, Human gene therapy.
[19] R. Crystal,et al. In vivo adenovirus-mediated gene transfer of the Escherichia coli cytosine deaminase gene to human colon carcinoma-derived tumors induces chemosensitivity to 5-fluorocytosine. , 1995, Human gene therapy.
[20] S. Kim,et al. Radiosensitization by 5-fluorocytosine of human colorectal carcinoma cells in culture transduced with cytosine deaminase gene. , 1996, Clinical cancer research : an official journal of the American Association for Cancer Research.
[21] M. Mehtali,et al. Efficient generation of recombinant adenovirus vectors by homologous recombination in Escherichia coli , 1996, Journal of virology.
[22] D. Klatzmann,et al. Prodrug-activated gene therapy: involvement of an immunological component in the "bystander effect". , 1996, Cancer gene therapy.
[23] Moolten Fl. Drug sensitivity ("suicide") genes for selective cancer chemotherapy. , 1994 .
[24] H. Wakimoto,et al. In vivo gene therapy for alpha-fetoprotein-producing hepatocellular carcinoma by adenovirus-mediated transfer of cytosine deaminase gene. , 1997, Cancer research.
[25] J. de Montigny,et al. The FUR1 gene of Saccharomyces cerevisiae: cloning, structure and expression of wild-type and mutant alleles. , 1990, Gene.
[26] C. Myers. The pharmacology of the fluoropyrimidines. , 1981, Pharmacological reviews.
[27] A. Rehemtulla,et al. Enzyme/prodrug therapy for head and neck cancer using a catalytically superior cytosine deaminase. , 1999, Human gene therapy.
[28] K. Willecke,et al. Bystander killing of cancer cells by herpes simplex virus thymidine kinase gene is mediated by connexins. , 1996, Proceedings of the National Academy of Sciences of the United States of America.
[29] M. Moyer,et al. Lack of bystander killing in herpes simplex virus thymidine kinase-transduced colon cell lines due to deficient connexin43 gap junction formation. , 1998, Human gene therapy.
[30] R. Blaese,et al. Transfer of the bacterial gene for cytosine deaminase to mammalian cells confers lethal sensitivity to 5-fluorocytosine: a negative selection system. , 1992, Proceedings of the National Academy of Sciences of the United States of America.
[31] F. Moolten. Tumor chemosensitivity conferred by inserted herpes thymidine kinase genes: paradigm for a prospective cancer control strategy. , 1986, Cancer research.
[32] Y. Shiratori,et al. Adenovirus-mediated transduction of Escherichia coli uracil phosphoribosyltransferase gene sensitizes cancer cells to low concentrations of 5-fluorouracil. , 1998, Cancer research.
[33] D. Brough,et al. Adenoviral vectors for gene transfer. , 1997, Current opinion in biotechnology.
[34] C. Mcginn,et al. Radiosensitizing nucleosides. , 1996, Journal of the National Cancer Institute.
[35] P. Erbs,et al. Characterization of the Saccharomyces cerevisiae FCY1 gene encoding cytosine deaminase and its homologue FCA1 of Candida albicans , 1997, Current Genetics.
[36] R. Blaese,et al. Tumors expressing the cytosine deaminase suicide gene can be eliminated in vivo with 5-fluorocytosine and induce protective immunity to wild type tumor. , 1994, Cancer research.
[37] E. Austin,et al. A first step in the development of gene therapy for colorectal carcinoma: cloning, sequencing, and expression of Escherichia coli cytosine deaminase. , 1993, Molecular pharmacology.
[38] C. Richards,et al. Metabolism of 5-fluorocytosine to 5-fluorouracil in human colorectal tumor cells transduced with the cytosine deaminase gene: significant antitumor effects when only a small percentage of tumor cells express cytosine deaminase. , 1994, Proceedings of the National Academy of Sciences of the United States of America.
[39] C. Richards,et al. In vivo antitumor activity of 5-fluorocytosine on human colorectal carcinoma cells genetically modified to express cytosine deaminase. , 1993, Cancer research.
[40] W. Anderson,et al. Intercellular communication mediates the bystander effect during herpes simplex thymidine kinase/ganciclovir-based gene therapy of human gastrointestinal tumor cells. , 1998, Human gene therapy.
[41] K. Sikora,et al. Gene therapy for cancer using tumour-specific prodrug activation. , 1994, Gene therapy.